Safety Pharmacology Society 2023 Annual Meeting

A number of HESI Committees will be presenting at the 2023 SPS Annual Meeting.

Botanical Safety Consortium

• From neat compounds to complex mixtures: A potential screening strategy for cardiotoxic potential of botanicals. P132. Presented by Matthias Gossmann, innoVitro GmbH & Jennifer Pierson, HESI

Cardiac Safety Committee

• An Evaluation of Drug-Induced Blood Pressure Changes in a Standard Canine CV Safety Pharmacology Study: A HESI-sponsored consortium, Koshman et al., P26. Presented by Yevgeniya Koshman, AbbVie
• In Vitro Assessment of Long-Term Cardiotoxicity Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes, Kettenhofen et al. P107. Presented by Ralf Kettenhofen, Fraunhofer IBMT
• Development of a Pharmaceutical Database to support the Nonclinical Evaluation of Drug-Induced Cardiac Toxicity, De Alwis et al., P138. Presented by Jennifer Pierson, HESI
• Heart Rate Corrected JTp and TpTe as Proarrhythmia Biomarkers in Safety Pharmacology Non-Human Primate Studies: Outcome from a HESI Consortium Prospective Study, Authier et al., P025. Presented by Todd Wisialowski, Pfizer
• The Impact of Collaborative Science on Cardiovascular Safety Evaluation – A 10-Year Update of the HESI Cardiac Safety Committee, Blinova et al., P140. Presented by Jennifer Pierson & Claire O'Brien, HESI

View meeting website here.